This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 1992:15 Suppl 1 Pt A:180A-181A.

doi: 10.1097/00002826-199201001-00095.

Risperidone, a new antipsychotic with serotonin 5-HT2 and dopamine D2 antagonistic properties

S L Heylen¹, Y G Gelders

Affiliations

PMID: 1379877
DOI: 10.1097/00002826-199201001-00095

Clinical Trial

Risperidone, a new antipsychotic with serotonin 5-HT2 and dopamine D2 antagonistic properties

S L Heylen et al. Clin Neuropharmacol. 1992.

. 1992:15 Suppl 1 Pt A:180A-181A.

doi: 10.1097/00002826-199201001-00095.

Authors

S L Heylen¹, Y G Gelders

Affiliation

¹ Janssen Research Foundation, Dept. Clinical R&D CNS, Beerse, Belgium.

PMID: 1379877
DOI: 10.1097/00002826-199201001-00095

No abstract available

PubMed Disclaimer

Similar articles

Risperidone.
Cohen LJ. Cohen LJ. Pharmacotherapy. 1994 May-Jun;14(3):253-65. Pharmacotherapy. 1994. PMID: 7524043 Review.
Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone.
Busatto GF, Pilowsky LS, Ell PJ, Costa DC, Verhoeff NP, Kerwin RW. Busatto GF, et al. Br J Psychiatry. 1993 Dec;163:833-4. doi: 10.1192/bjp.163.6.833. Br J Psychiatry. 1993. PMID: 7508329 No abstract available.
Efficacy of risperidone on positive features of schizophrenia.
McEvoy JP. McEvoy JP. J Clin Psychiatry. 1994 May;55 Suppl:18-21. J Clin Psychiatry. 1994. PMID: 7520904 Clinical Trial.
Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients.
Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, Ericsson B. Farde L, et al. J Clin Psychopharmacol. 1995 Feb;15(1 Suppl 1):19S-23S. doi: 10.1097/00004714-199502001-00004. J Clin Psychopharmacol. 1995. PMID: 7537284
A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors.
He H, Richardson JS. He H, et al. Int Clin Psychopharmacol. 1995 Mar;10(1):19-30. doi: 10.1097/00004850-199503000-00003. Int Clin Psychopharmacol. 1995. PMID: 7542676 Review.

See all similar articles

Cited by

Risperidone dose for schizophrenia.
Li C, Xia J, Wang J. Li C, et al. Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD007474. doi: 10.1002/14651858.CD007474.pub2. Cochrane Database Syst Rev. 2009. PMID: 19821422 Free PMC article.
Cortical Gray Matter Injury in Encephalopathy of Prematurity: Link to Neurodevelopmental Disorders.
Fleiss B, Gressens P, Stolp HB. Fleiss B, et al. Front Neurol. 2020 Jul 14;11:575. doi: 10.3389/fneur.2020.00575. eCollection 2020. Front Neurol. 2020. PMID: 32765390 Free PMC article. Review.
Risperidone versus typical antipsychotic medication for schizophrenia.
Kennedy E, Song F, Hunter R, Clarke A, Gilbody S. Kennedy E, et al. Cochrane Database Syst Rev. 2000;2003(2):CD000440. doi: 10.1002/14651858.CD000440. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2003;(2):CD000440. doi: 10.1002/14651858.CD000440. PMID: 10796543 Free PMC article. Updated.
Antipsychotic medication for early episode schizophrenia.
Bola J, Kao D, Soydan H. Bola J, et al. Cochrane Database Syst Rev. 2011 Jun 15;2011(6):CD006374. doi: 10.1002/14651858.CD006374.pub2. Cochrane Database Syst Rev. 2011. PMID: 21678355 Free PMC article.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information